💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Metoprolol

CHEMBL13 Phase 4 معتمد Small molecule
Half-Life
3-7 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
267.4 g/mol
LogP
1.9
Phase
4

This beta-blocker slows the heart rate and reduces the heart's workload by blocking the effects of adrenaline. It is prescribed for conditions such as high blood pressure, irregular heart rhythms, and heart failure.

الوزن الجزيئي

267,3640 g/mol

LogP

1,90

TPSA

50,70 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Cardiovascular Disease Pain Management Non-Small Cell Lung Cancer Asthma Chronic Obstructive Pulmonary Disease Migraine Psoriasis Chronic Kidney Disease Stroke Hyperlipidemia Obesity Type 2 Diabetes Hypertension Breast Cancer Atopic Dermatitis Chronic Pain Malaria Hepatitis C Heart Failure Atrial Fibrillation Leukemia

تصنيفات الأدوية

C — C - Cardiovascular System

آلية العمل

Selective beta-1 adrenergic receptor blocker.

Pharmacokinetics (PK)

Half-Life 3-7 hours

Pharmacodynamics (PD)

الآلية

Selective beta-1 adrenergic receptor blocker.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COCCc1ccc(OCC(O)CNC(C)C)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H25NO3

                    

                    
                    

                        
HBD / HBA

                        
2 / 4

                    

                    
                    

                        
الروابط القابلة للدوران

                        
9

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
19

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            ADRB1 (Beta-1 Adrenergic Receptor)
                            Antagonist
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            ADRB2 (Beta-2 Adrenergic Receptor)
                            Antagonist
                        

                        
                    

                    
                    

                        

                            CYP2D6 (Cytochrome P450 2D6)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Metoprolol + Tacrolimus
                            
                        

                        
                        
Tacrolimus may mildly prolong the QT interval; metoprolol's bradycardic effect may compound this modestly, though clinically significant arrhythmia is uncommon at standard doses.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Metoprolol + Diltiazem
                            
                        

                        
                        
Diltiazem combined with metoprolol increases the risk of bradycardia and AV block through additive negative chronotropic and dromotropic effects.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Metoprolol + Digoxin
                            
                        

                        
                        
Metoprolol adds to digoxin's rate-slowing effect at the AV node, increasing the risk of bradycardia and AV block in susceptible patients.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Metoprolol + Insulin Glargine
                            
                        

                        
                        
Beta-blockers such as metoprolol mask the adrenergic warning symptoms of hypoglycaemia (tachycardia, tremor) and may prolong hypoglycaemic episodes in insulin-treated patients.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Metoprolol + Bupropion
                            
                        

                        
                        
Bupropion is a potent CYP2D6 inhibitor that substantially increases metoprolol plasma concentrations, potentially causing excessive beta-blockade (bradycardia, hypotension, heart block).

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
This beta-blocker slows the heart rate and reduces the heart's workload by blocking the effects of adrenaline. It is prescribed for conditions such as high blood pressure, irregular heart rhythms, and heart failure.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective beta-1 adrenergic receptor blocker.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Metoprolol: Half-life: 3-7 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Metoprolol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Atorvastatin
                            Small molecule
                        
                        
                        
                            Amlodipine
                            Small molecule
                        
                        
                        
                            Lisinopril
                            Small molecule
                        
                        
                        
                            Losartan
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL13.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4171.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.